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AKTIVITI ANTIDIABETIK EKSTRAK BUAH PHALERIA 
MACROCARPA (Scheff.) Boerl 
ABSTRAK 
       Buah Phaleria macrocarpa digunakan dalam perubatan tradisional di Indonesia dan 
bahagian timur Malaysia sebagai ubat untuk pengurusan diabetes mellitus. Oleh itu, 
kajian ini dijalankan untuk mengkaji aktiviti antidiabetik buah-buahan ini dalam tikus 
normal dan tikus diabetik aruhan streptozotocin (STZ). Buah-buahan kering yang 
dikisar lumat diekstrak secara berturutan dalam petroleum eter, metanol dan air. 
Kesemua ekstrak (1 g/kg) tidak menunjukkan  kesan terhadap glukosa darah tikus 
normal. Ekstrak metanol dan air merencat secara signifikan kenaikan glukosa darah 
tikus normal yang diberi beban glukosa dalam ujian toleransi glukosa intra-peritoneal 
(IPGTT). Selepas rawatan oral harian selama 12 hari, hanya ekstrak metanol (ME) 
menurunkan paras glukosa darah (P<0.05) tikus diabetik. Ekstrak metanol kemudian 
disisihkan untuk mendapatkan fraksi klorofom (CF), etil asetat (EAF), n-butanol (NBF) 
dan akueus (AF). Dalam IPGTT, NBF merencat secara signifikan (P<0.05) kenaikan 
paras glukosa darah selepas diberi beban glukosa dalam tikus normal. Rawatan oral 
harian dengan NBF selama 12 hari juga menurunkan paras glukosa darah (P<0.05) tikus 
diabetik. Oleh itu, NBF seterusnya disisihkan kepada sub-fraksi I (SFI) dan sub-fraksi II 
(SFII). SFI merencat secara signifikan (P<0.05) kenaikan glukosa darah dalam IPGTT 
dan menurunkan insulin plasma (P<0.05) bersama-sama dengan glukosa dalam tikus 
diabetik. NBF menunjukkan aktiviti perencatan yang tertinggi terhadap α-glukosidase 
(75%) dan α-amilase (87%) secara in vitro. In vivo, dalam tikus diabetik, NBF dan SFI 
juga didapati berupaya menindas puncak glukosa darah (PBG) sebanyak 15.08% dan 
6.46%, masing-masing, menyebabkan penurunan dalam  kawasan di bawah keluk 
xvii 
 
(AUC) sebanyak 14.23% dan 12.46%, masing-masing, selepas cabaran sukrosa oral. 
Kesan penindasan terhadap PBG dan AUC juga dilihat dalam ujian toleransi kanji dan 
glukosa, tetapi hingga takat yang lebih rendah. Keputusan ini mencadangkan perencatan 
oleh enzim pencernaan α-glukosidase dan α-amilase mungkin menyumbang kepada 
aktiviti antidiabetik P. macrocarpa. Penyaringan fitokimia menunjukkan kehadiran 
flavonoid, terpena dan tanin di dalam ME, NBF dan SFI. Analisis LC-MS mendedahkan 
kehadiran mangiferin dalam ME (9.52%), NBF (33.30%) dan SFI (22.5 %). Kesan in 
vivo dan in vitro bagi ekstrak dan fraksi-fraksi ini kelihatan  berkolerasi dengan 
kandungan mangiferin yang mencadangkan bahawa mangiferin mungkin 
bertanggungiawab untuk kesan antidiabetik yang diperhatikan. 
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ANTIDIABETIC ACTIVITY OF PHALERIA MACROCARPA (Scheff.) 
Boerl FRUIT EXTRACTS 
 
ABSTRACT 
       The fruit of Phaleria macrocarpa is used in traditional medicine in Indonesia and 
the eastern part of Malaysia, as a remedy for the management of diabetes mellitus. This 
study was therefore carried out to investigate the antidiabetic activity of this fruit in 
normal and streptozotocin (STZ) -induced diabetic rats. The pulverized dried fruits were 
sequentially extracted in petroleum ether, methanol and water. None of the extracts      
(1 g/kg) exerted an effect on blood glucose of normal rats.  The methanol and water 
extracts significantly inhibited the rise of blood glucose after glucose loading in intra-
peritoneal glucose tolerance tests (IPGTT) in normal rats. After 12 days daily of oral 
treatment, only methanol extract (ME), lowered the blood glucose (P<0.05) level of 
diabetic rats. The methanol extract was then fractionated to obtain chloroform (CF), 
ethyl acetate (EAF), n-butanol (NBF) and aqueous (AF) fractions. In IPGTT, NBF 
significantly inhibited the rise of blood glucose levels (P<0.05) after glucose loading in 
normal rats. Daily oral treatment of NBF for 12 days also lowered blood glucose level 
(P<0.05) of diabetic rats. NBF was therefore further fractionated into sub-fractions I 
(SFI) and sub-fraction II (SFII). SFI significantly inhibited the rise of blood glucose 
(P<0.05) in IPGTT and lowered plasma insulin (P<0.05) along with glucose in diabetic 
rats. NBF showed the highest inhibitory activity against α-glucosidase (75%) and α-
amylase (87%) in vitro. In vivo, in diabetic rats, NBF and SFI were also found to 
suppress peak blood glucose (PBG) by 15.08% and 6.46%, respectively, resulting in a 
reduction in the area under the curve (AUC) by 14.23% and 12.46%, respectively, after 
an oral sucrose challenge (P<0.05). The suppressive effects on PBG and AUC were also 
xix 
 
demonstrated in glucose and starch tolerance test, but to a lesser extent. It suggests that 
the inhibition by digestive enzymes α-glucosidase and α-amylase may have contributed 
to the antidiabetic activity of P. macrocarpa fruit. Phytochemical screening showed the 
presence of flavonoids, terpenoids and tannins, in ME, NBF and SFI. LC-MS analyses 
revealed the presence of mangiferin in ME (9.52%), NBF (33.30%) and SFI (22.50%). 
The in vivo and in vitro effect of these extract and fractions seems to be correlated with 
their mangiferin content which suggests that mangiferin may be responsible for the 
observed antidiabetic effects.    
 
1 
 
CHAPTER ONE: INTRODUCTION 
 
1.1. Background  
        Daily meals should always contain a combination of carbohydrate, protein, fat, 
fiber, vitamins and minerals from bread, meat, oil, vegetables and fruits. The digestion 
process starts with amylase in the mouth, through the oesophagus and finally into the 
intestine. In the intestine, digested food converted into building blocks namely glucose, 
amino acids and fatty acids which are absorbable by the intestine. Glucose is a universal 
source of energy, especially for brain cells. As blood glucose reaches the postprandial 
level, a signal automatically triggers the pancreas to release the hormone insulin into the 
blood-stream. At this point, cells can utilise the glucose which is readily available. Any 
excessive glucose is stored in liver and muscle cells as polymeric glycogen with the 
help of insulin as well. This stored glucose can be consumed when it is required. It is 
clear how important insulin is to the body, especially for glucose control.  The presence 
of glucose may not be recognized should insulin fail to work properly; this condition 
could lead to hyperglycaemia in the blood and an insufficient supply to the cells. 
Consequently, cells keep converting alternative sources of energy such as fat from lipid-
rich tissues and protein from muscles into glucose. This alternative metabolism could 
lead to body weight loss and fatigue (Sonksen et al., 2003).  
1.2. Diabetes Mellitus 
        Diabetes mellitus is one of the most common chronic diseases in nearly all 
countries. The number increases significantly as a consequence of lifestyle changes 
involving the lack of physical activities and indirectly mirrors the increase in obesity 
(Shaw et al., 2010). Diabetes is classified into two main types by the underlying causes, 
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which are type I (insulin dependent diabetes mellitus, IDDM) and type II (non-insulin 
dependent diabetes mellitus, NIDDM). Anti-diabetic medications treat diabetes mellitus 
by lowering glucose levels in the blood. There are different classes of anti-diabetic 
drugs and the selection depends on the nature of the diabetes, age and the patient’s 
condition as well as some other related factors.   
       IDDM occurs mostly in children and young adults, who comprise 20% of diabetics. 
In this condition, there is no option other than treatment with insulin’s injection; insulin 
is the sole choice to control IDDM. The hormone needs to be injected subcutaneously 
since it would be destroyed if taken orally. In contrast to IDDM, patients with NIDDM 
would have higher levels of insulin; this is the reason why NIDDM patients are 
diagnosed later than IDDM patients, usually after symptoms or complications have 
appeared. However, NIDDM usually affects only adults, especially the obese, since 
obesity enhances peripheral insulin resistance. Oral hypoglycaemic agents that induce 
more insulin production, sensitize tissue towards insulin and prevent excessive glucose 
absorption are available for NIDDM patients. Two main classes used are sulfonylureas 
(e.g. glibenclamide) and biguanides (e.g. metformin) that can be taken individually or in 
combination. Obese patients are advised to take biguanides as sulfonylureas causes 
weight gain (Sonksen et al., 1998). The number of people with diabetes is expected to 
increase from 1,846,000 in 2010 to 3,254,994 in 2030, and the adjusted prevalence of 
diabetes (adjusted to world population) in Malaysia will rise from 11.6% in 2010 to 
13.8% in 2030 (International Diabetes Federation, 2009).  
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1.3. Pancreas 
       Pancreas could always be considered as a mixed gland due to its multi-functions 
capability. It can function as an exocrine and endocrine gland. As an exocrine gland, it 
acts as a digestive organ by which it secretes the digestive enzymes as well as alkaline 
materials and channels these into the small intestine via duct. As an endocrine gland in 
it secretes hormones into the blood-stream. However, the endocrine area makes up only 
1% out of the total weight of the pancreas (Gerard et al., 1999).   
       Islets consist of four special groups of cells namely alpha (α) cells that produce 
glucagon to increase the blood glucose level, beta (β) cells that produces insulin to 
lower the glucose level, delta (δ) cells that secretes somatostatin and hypothalamic 
inhibiting hormone which also inhibits the secretion of glucagon and insulin, and finally 
F cells which secretes pancreatic polypeptides into the bloodstream and regulates the 
release of pancreatic digestive enzymes. Insulin would acts together with glucagon to 
regulate glucose metabolism (Donna et al., 1995).   
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Figure 1.1. Pancreas system 
1.3.1. Glucagon  
       Briefly, glucagon consists of 29 amino acids (polypeptide hormone) from the α-islet 
cells which acts as a physiological regulator of insulin effect in response to 
hypoglycaemia (Laurence and Bennett, 1995). As the blood glucose level falls, it 
stimulates the liver to convert glycogen into glucose (glycogenolysis) so as to increase 
the glucose concentration. In this case, glucagon also stimulates the glycogenolysis, a 
process which converts non-carbohydrate sources (amino acids, lactic acid etc.) into 
glucose. It also stimulates fatty acids and glycerol release from adipose tissue. Apart 
from that, glucagon also helps to increase the concentration of AMP cyclic derived from 
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ATP in liver cells by activating the phosphorylase enzyme. This enzyme separates 
glucose units from a larger form of the glycogen molecule and boosts the free glucose 
units entering the bloodstream. Thus, during fasting or any time that the blood glucose 
level drops below normal (70-110 mg/dl), glucagon acts to increase the glucose level to 
normal. For this reason, it is considered as a hyperglycaemic factor (Donna et al., 1995). 
1.3.2. Insulin  
      Insulin is synthesized as a large peptide (35 amino acids) containing A and B chains 
with an additional sequence of 16 amino acids connected as pre-proinsulin. These 16 
amino acids cleaved to form proinsulin which is then hydrolysed to insulin (connected 
to peptide in humans) which is called the C-peptide (31 amino acids). Then, this links a 
threonine residue in the B chains to a glycine in the A chain (Joseph and Digregorio, 
1990). β-islets cells-synthesize, release and store insulin with daily secretion in the 
range of 30-40 units which is equivalent to 25% of total pancreatic insulin content. A 
high blood glucose concentration is the principal factor that evokes insulin secretion 
(Laurence and Bennett, 1995). 
1.4. Oral anti-diabetic drugs  
     The β-cell has emerged as one of the most attractive molecules that could provide a 
number of potential new targets in drugs development. Intensive treatment of IDDM is 
designed to prevent the development of micro-vascular and neurological complications, 
which are most likely also applicable for NIDDM (Ohkubo et al., 1995). However, 
treatment for NIDDM aims to mitigate symptoms via normalisation or near-
normalisation of fasting and postprandial blood glucose levels as well as to prevent 
acute or long-term complications. There are several approaches to improving glucose 
homeostasis; however those that are currently applied in clinical practice are either 
unsuccessful in restoring normoglycaemia or fail after a period of time. The classes of 
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drugs that are readily available for glycaemic regulation are Suphonylureas (e.g. 
glibenclamide), Biguanides (e.g. metformin), Thiazolidinediones (e.g. pioglitazone),      
α-glucosidase inhibitors (e.g. acarbose), Dipeptidyl Peptidase (DPP)-IV Inhibitor and 
Insulin. Each of them differs by mode and site of action. These standard 
pharmacological treatments might be applied either individually or in combination, and 
provide more ideal glycaemic control in selected and identified patients (Gerard et al., 
1999).  
Table 1.1. Oral diabetes medications summary (Eurich, et al., 2007) 
Diabetes Pills How to Take How They Work Side Effects 
Biguanides 
Metformin 
(Glucophage)  
Metformin liquid  
( Riomet) 
 
Metformin extended   
 release  (Glucophage 
XR, Fortamet, 
Glumetza) 
Metformin: 
usually taken 
twice a day with 
breakfast and 
evening meal. 
 
Metformin 
extended release: 
usually taken once 
a day in the 
morning. 
Decreases amount 
of glucose released 
from liver. 
Bloating, gas, 
diarrhea, upset 
stomach, loss of 
appetite (usually 
within the first few 
weeks of starting). 
Take with food to 
minimize 
symptoms. 
Metformin is not 
likely to cause low 
blood glucose. In 
rare cases, lactic 
acidosis may occur 
in people with 
abnormal kidney or 
liver function. 
Sulfonylureas  
 
Glimepiride (Amaryl)  
 
Glyburide  (Diabeta, 
Micronase) 
 
Glipizide (Glucotrol, 
Glucotrol XL) 
 
Micronized glyburide 
(Glynase) 
 
 
Take with a meal 
once or twice a 
day. 
Stimulates the    
pancreas to release 
more insulin, both 
right after a meal 
and then over 
several hours 
Low blood glucose, 
occasional skin 
rash, irritability, 
upset stomach 
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Meglitinides 
Repaglinide (Prandin) 
 
D-Phenylalanine 
Derivatives 
 
Nateglinide (Starlix) 
 
Both of these 
medications 
should be taken 
with meals. If you 
skip a meal, skip 
the dose 
Stimulate the 
pancreas to release 
more insulin right 
after a meal. 
Effects diminish 
quickly and they 
must be taken with 
each meal; may 
cause low blood 
glucose. 
Thiazolidinediones 
Pioglitazone (TZDs) 
 
Pioglitazone 
(Actos) 
 
 
 
 
 
 
 
 
 
Usually taken once 
a day; take at the 
same time each 
day. 
Makes the body 
more sensitive to 
the effects of 
insulin. 
May cause side 
effects such as 
swelling (edema) or 
fluid retention. 
 
Do not cause low 
blood sugar when 
used alone. 
 
Increased risk of 
congestive heart 
failure in those at 
risk. 
DPP-4 Inhibitors 
 
Sitagliptin (Januvia) 
 
Saxagliptin (Onglyza) 
 
Linagliptin(Tradjenta) 
 
Take once a day at 
the same time each 
day 
Improves insulin 
level after a meal 
and lowers the 
amount of glucose 
made by your body 
Stomach 
discomfort, 
diarrhea, sore 
throat, stuffy nose, 
upper respiratory 
infection. 
 
Do not cause low 
blood glucose. 
Alpha-glucosidase 
Inhibitors 
 
Acarbose  
(Precose) 
 
Miglitol  
(Glyset) 
 
Take with first bite 
of the meal; if not 
eating, do not take. 
Slows the 
absorption of 
carbohydrate into 
your bloodstream 
after eating. 
Gas, diarrhea, upset 
stomach, abdominal 
pain 
Bile Acid  
Sequestrants 
  
Colesevelam 
(Welchol) 
Take once or twice 
a day with a meal 
and liquid. 
Works with other 
diabetes 
medications to 
lower blood 
glucose. 
Constipation, 
nausea, diarrhea, 
gas, heartburn, 
headache (may 
interact 
 with glyburide, 
levothyroxine and 
contraceptives) 
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1.5. Medicinal Plants 
      Plants have been an exemplary source of medicine since ancient times. They have 
played key roles in traditional health care systems and, on the basis of this, have formed 
a significant percentage of allopathic and modern drugs in many nations of the world 
(Grover et al., 2002; Samy and Gopalakrishnakone, 2007). Be that as it may, to a large 
extent, these plants have not been valued by modern science, until recently when it 
became clear from empirical evidence in traditional medicine, that most pathological 
conditions are understood only in part, and can be traditionally managed with 
unimaginable efficacy, thereby warranting the current herbal renaissance going on 
around the world which is highly powered by the environmental drive to go green (Joy 
et al., 1998). Medicinal plants are therefore gaining reputation for use as modern 
alternatives to orthodox medicines or as complementary products to maintain health or 
treat aspects of diseases, particularly those in which orthodox medication has had 
limited success (Houghton, 2009). 
          Diabetes is one such disease that has been managed with only limited success by 
“Western” medicine. Conventional efforts aimed at improved management of this 
disease have been disappointing and the control of blood glucose level remains 
unsatisfactory, as is reflected in steady increases in diabetes morbidity and mortality 
rates (Shaw et al., 2010). Consequently, the current prospective focus for appropriate 
antidiabetic agents is herbal medicine. There is however, a need for in-depth 
investigation to confirm and advocate the excellence of these plants over existing 
therapies, such as elucidation of their mechanism(s) of action and therapeutic effects, as 
the antidiabetic evidence of some of them is anecdotal (Jelodar et al., 2007). 
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1.6. Research on Herbs 
      With the massive growth and high demand in the global market for herbal remedies, 
this field is estimated to grow up to USD 5 trillion in 2050 from USD 80 billion in 2000 
with projected growth of USD 20 billion in 2008 (Norawi, 2002). This has boosted 
interest in conducting herbal research to fulfill demands. This includes plants bioactivity 
screening based on the inputs and claims of folklore. The WHO of Regional Office for 
the Western Pacific has come up with a research guideline in evaluating the safety and 
efficacy of herbal medicines (WHO, 1992). It gives special attention to the concept of 
polypharmacy in herbal preparations where the isolation of a single active substance 
with therapeutic value may not be necessary. However, the isolation of an active 
substance will remain useful in providing an exact dosage and determining any adverse 
reaction to the active substance (WHO, 1992). 
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1.7. Phaleria macrocarpa (Scheff.) Boerl 
Kingdom              : Plantae  
Subkingdom        : Tracheobionta 
Super Division    : Spermatophyta  
Division               : Magnoliphyta 
Class                    : Magnolipsida  
Subclass               : Rosid 
Order                    : Myrtales 
Family                  : Thymelaeaceae  
Genus                   : Phaleria 
Species                : Phaleria Macrocarpa  (Scheff) Boerl 
 
       Phaleria macrocarpa (Scheff) Boerl is a shrub or small tree; usually up to 5 meters 
(Winarto, 2003; Harmanto, 2005) and the height sometimes could also reach up to 18 
meters. It features many branched crown, a large straight root (one meter long) exuding 
sap, a brownish green bark and white wood. It has green tapering leaves, 7-10 cm length 
and 3-5 cm width. Its flowers form a compound of 2-4 flowers, little white trumpet - 
like fragrant flowers. The fruit comes in various sizes and the color varying from green 
to maroon. The pit is in a round shape, white in color and very poisonous. It grows in 
areas of 10–1200 m above the sea level, and best in areas of 1000 m above the sea level 
with its productive age estimated to be in between 10-20 years. 
     For centuries, the native Indonesians have used the fruits and leaves of the Mahkota 
Dewa (literally translated as God’s Crown) tree, P. macrocarpa (Scheff.) Boerl., to 
combat diabetes, liver diseases, vascular problems, cancer, and high blood pressure. 
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Recent research has proven that P. macrocarpa contains plant secondary metabolites 
that could combat not only cancers or infectious disease such as malaria, but also the    
so-called lifestyle diseases (Harmanto, 2005). Parts of P. macrocarpa that are used for 
medical treatments are the stems, leaves and fruits. Empirically, P. macrocarpa is 
proven capable of controlling cancer, impotency, dysentery, hemorrhoid, diabetes 
mellitus, allergies, liver and heart diseases, kidney disorders, blood diseases, arthritis, 
rheumatism, high blood pressure, stroke, migraine, various skin diseases, acne and the 
level of cholesterol. This plant contains antihistamine, antioxidant and anti-cancer 
substances (Harmanto, 2005). 
    Kusmardiyani and co-workers (2004) isolated a white yellowish and odorless 
crystalline compound from the ethanolic extract of P. macrocarpa leaves. The isolate 
was presumed as a benzophenone glucoside based on its ultraviolet, infrared, mass, 1H 
and 13C NMR spectra. Another benzophenoic glucoside known as 4,5-dihydroxy,4’- 
methoxybenzophenone-3-O-ß-D-glucoside or Phalerin was also isolated from the 
methanolic extract of the leaves of P. macrocarpa. Phalerin was cytotoxic to myeloma 
cell line (NS-1) having IC50 of 83μg/ml or 1.9x10-1 mM (Mae, et al., 2005). 
      A lignan which is similar to syringaresinol was isolated by Lisdawati (2002) from 
the ethyl acetate fraction of P. macrocarpa‘s mesocarp. The isolate was elucidated by 
using ultraviolet – visible spectroscopy (UV-Vis) spectra data, Fourier transform infra 
red (FTIR) spectrometric, liquid chromatography–mass spectrometry (LC-MS), and the 
proton nuclear magnetic resonance spectral data 1H–RMI and combination of 2D 
1H,1H-COSY, TOCSY and NOESY RMI. The spectral evidence show molecule 
structures of the isolate was C19H20O6: 5-[4(4-Methoxy-phenyl)-tetrahydrofuro[3,4-c] 
furan-1-yl]-benzene- 1,2,3-triol. Besides, P. macrocarpa too contains gallic acid which 
can exhibit a significant inhibition of cell proliferation in a series of cancer cells and 
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induction of apoptosis in esophageal cancer cell but not in non - cancerous cell (Faried, 
et al., 2007). 
      Hendra, et al., (2011) reported that methanol extract of various parts of                     
P. macrocarpa could be considered as a natural antimicrobial source due to the presence 
of flavonoid compounds. Flavonoid compound present in P. macrocarpa fruits were 
analyzed by using Reversed Phase-High Performance Liquid Chromatography (RP-
HPLC). Kaempferol, myricetin, naringin, and rutin were found as flavonoid compounds 
in pericarp of P. macrocarpa. It was also confirmed the presence of naringin and 
quercetin in mesocarp. Apart from that, the seed of P. macrocarpa fruits were reported 
only contain quercetin.    
      Triastuti, et al., (2008) reported that the ethyl acetate of P. macrocarpa had diabetic 
activity against alloxan - induced diabetic rats which is mediated either by preventing 
the decline of hepatic antioxidant status or due to its indirect radical scavenging 
capacity. Triastuti, et al., (2009) have also reported that the methanol extract and its 
fraction of P. macrocarpa consist of anti-hyperglycemic and anti - nephropathy of        
P. macrocarpa. This may be correlated to the increase of renal antioxidant enzyme 
activity in alloxan - induced diabetic rats. 
     Sugiwati, et al., (2006) reported that the n-butanol of young and ripe fruit extracts of 
P. macrocarpa contain the highest inhibitory activity followed by ethyl acetate and 
methanol extracts of in vitro α-glucosidase. By oral administration to rats, the 
hypoglycemic activity showed that the boiled water extract and n-butanol extracts of 
ripe fruit (at a certain dose) had significantly decreased the blood glucose concentration 
of rats after been treated with 80% w/v sugar solution, being comparable to those of 
acarbose rats as the positive control.  
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       Sugiwati, et al., (2009) has also reported that the ethyl acetate which was extracted 
from the old leaves of P. macrocarpa has given the highest inhibition activity based on 
α-glucosidase inhibition test compared to the young leaves. The inhibition activity from 
the methanol and boiled water extracts of old leaves too were found to be greater and 
higher than that of young leaves. In addition,  
     Oshimi, S et al., (2007) had isolated icariside C3, phalerin and mangiferin from the 
fruits of P. macrocarpa. Based on this study, the icariside C3 showed a slow 
vasorelaxant activity against noradrenalin-induced contraction of isolated rats’ aorta. 
      Sellamuthu, et al., (2009) reported that mangiferin purified from methanolic root 
extract of Salacia chinensis has the antihyperglyceamic activity in normal and 
streptocotozin-induced diabetic rats. The mangiferin was administrated orally at a dose 
of 40 mg/kg weight per day (30 days) to STZ-induced diabetic rats. The mangiferin 
treated diabetic rats significantly decreased the level of blood glucose, glycosylated 
hemoglobin as well as increased level of insulin and hemoglobin.  
      Miura, et al., (2001) isolated mangiferin from Anemarrhena asphodeloides Bunge 
rhizome, and tested for antidiabetic activity in KK-Ay mice, an animal model of type-2 
diabetes. They found that MF lowered the blood glucose level of KK-Ay mice three 
weeks after oral administration. 
      Miura, et al., (2001) also reported that water extract of Anemarrhena asphodeloides 
Bunge rhizome (90 mg/kg) reduced blood glucose levels from 570 +/- 29 to 401 +/- 59 
mg/dl 7 h after oral administration (p<0.05) and also tended to reduce serum insulin 
levels in KK-Ay mice. Anemarrhena asphodeloides-treated KK-Ay mice had 
significantly reduced blood glucose levels in an insulin tolerance test. 
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    Iwamoto, et al,. (2000) reported that the antidiabetic action of mangiferin with 
exercise was investigated in KK-Ay mice, an animal model of type 2 diabetes. MF (30 
mg/kg) significantly decreased the blood glucose and insulin levels of KK-Ay mice with 
exercise two weeks after the oral administration, while control group (exercise only) did 
not changes. MF also significantly decreased blood triglceride level of KK-Ay mice. 
These finding indicate that MF with exercise is useful for the early stage symptom of 
type 2 diabetes. 
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 Figure 1.2. The plant Phaleria macrocarpa (Scheff) Boerl. (A) Whole plant. (B) Ripe   
  fruits. (C) Dried sliced fruits. (D) Ground fruits  
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1.4 Research Objectives 
       In this study, dried, sliced and ground P. macrocarpa fruits were extracted and the 
contents as well as the antidiabetic effect of each of the extract and some fractionated 
samples were evaluated, as described in chapter 2.   The objectives of the present study 
were: 
1. To study the hypoglycaemic and anti-hyperglycaemic activity of the extracts 
using hypoglycaemic and intra-peritoneal glucose tolerance tests (IPGTT). 
2. To determine the most active extract and the most active fraction in an 
attempt to identify the active compounds by bioactivity-guided fractionation 
technique. 
3. To evaluate the effect of most active extract, fraction and sub-fraction on α- 
glucosidase and alpha amylase inhibition in vitro and determine the IC50. 
4. To investigate the effect of the most active extract, fraction and sub-fraction 
of P. macrocarpa on in vivo alpha glucosidase inhibition tests on normal and 
diabetic rats. 
5. To perform a phytochemical screening study of chemical groups present in 
the most active extract, fraction and sub-fraction by TLC and LC-MS. 
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CHAPTER TWO: MATERIALS AND METHODS 
 
2.1. Instruments used and their sources 
Accu-check Advantage II Clinical Glucose meter Roche diagnostic Co. USA 
Electric grinder Apex-mill, Comminuting mill, England 
Flurescence Analysis Cabinet Westbury, USA 
Freeze dryer Labconco Cooperation, Denmark 
Freezer Forma Scientific, USA 
Hitachi U-2000 Spectrophotometer Hitachi, Japan 
Hot plate/Stirrer PMC Industries, USA 
Microplate reader Power Wave X340, USA 
Oral needle Popper & Sons, Inc, USA 
Oven Memmert, Germany 
Rotary evaporator Buchi, Switzerland 
Separatory funnel Schott, Duran, Germany 
Soxhlet-extractor   Buchi, Switzerland 
 TLC plate silica gel 60 F254 Merck, Germany 
Vacuum system  Buchi, Switzerland 
Vortex mixer (Model: VM-2000) VIH DER Instruments Co, Taiwan 
Water bath Brotech, Malyasia 
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2.2. Materials used and their sources 
3,5-Dinitrosalicylic acid Sigma Aldrich Chemical Co, US 
Acetic acid R & M Chem., UK 
Anisaldehyde reagent Sigma-Aldrich, Germany 
Anhydrous monobasic sodium phosphate  BDH Chemical Ltd, England 
Chloroform   Fisher Scientific, UK 
Dibasic sodium phosphate Sigma Aldrich Chemical Co, USA 
Dragendorff reagent Sigma-Aldrich, USA 
Ethyl acetate  Fisher Scientific, UK 
Formic acid R & M Chem., UK 
Glibenclamide  Novo Nordisk (Copenhagen,Denmark) 
Glucose monohydrate                Essex, USA 
Human insulin  100 IU/Ml Novo Nordisk (Copenhagen,Denmark) 
Mangiferin  Sigma-Aldrich, Germany 
Metformin  Novo Nordisk (Copenhagen,Denmark) 
Methanol  [CH3OH]                                        Fisher Scientific, UK  
n-butanol  Fisher Scientific, UK 
Natural product reagent Sigma-Aldrich, Germany 
Para – nitophenyl – α – glucopyranoside Sigma Aldrich Chemical Co, US 
Petroleum ether Fisher Scientific, UK 
Silica gel-7730 Merck, Germany 
Sodium chloride R & M Chemicals, Essex, UK 
Sodium hydroxide R & M Chemicals, Essex, UK 
Sodium potassium tartrate R & M Chemicals, Essex, UK 
19 
 
Starch Ajax Chemical, Sydney, Australia 
Streptozotocin  Sigma-Aldrich Chemical Co, USA 
Sulphuric acid [H2SO4] R & M Chem, UK 
Tween 80 R & M Chem., UK 
α-glucosidase from yeast  Sigma-Aldrich Chemical Co, US 
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2.3. Methods  
   2.3.1. Experimental animals 
      Healthy male Sprague Dawley (SD) rats weighing between 200-250g obtained from 
the Animal Research and Service Centre (ARASC), Universiti Sains Malaysia (USM) 
were used in the study. The animals were housed and kept at 25-30
0
C in the Animal 
Transit Room, School of Pharmaceutical Sciences, USM. They were allowed access to 
food (standard laboratory chow, Gold Coin Sdn. Bhd., Malaysia) and tap water ad 
libitum. The experimental procedures were approved by the Animal Ethics Committee 
of Universiti Sains Malaysia (USM) Penang, Malaysia. 
 
   2.3.2. Plant material collection and preparation of extracts 
       The dried fruits of P. macrocarpa Benth were collected from Kepala Batas, 
Seberang Perai, Pulau Pinang, Malaysia.  A voucher specimen of the plant (11259) is 
deposited at Herbarium of School of Biological Sciences, Universiti Sains Malaysia. 
These dried fruits were grounded into powder using a milling machine, and thereafter 
weighed and stored in air tight containers until use. A sample of 2400 g of the grounded 
plant was sequentially extracted with petroleum ether, then methanol using soxhlet 
apparatus (40
0
C) for 48 hours each. The residue from methanol extraction after 
complete drying was re-extracted with water by maceration at 60
0
C for 24 hours as 
shown in Figure 2.1. Each extraction step was repeated three times and the different 
extracts obtained were filtered with Whatman No. 1 filter paper and concentrated in 
vacuo by rotary evaporation (Buchi, Switzerland) at reduced pressure. The concentrated 
extracts were frozen at -70 
0
C for 48 hours then freeze-dried under vacuum for 24 hours. 
The dried extracts were kept in the freezer from where sample were withdrawn from 
time to time for test procedures. 
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                           Powdered P. macrocarpa (200 g) 
                                    Packed into a thimble of a soxhlet extraction 
                                     Extracted with petroleum ether (5 L)             
              
Marc of plant material                                                    Petroleum ether extract 
                                                                                                   (4.7 g) 
           Packed into a thimble of a soxhlet extraction           
            Extracted with methanol (5 L)             
 
Marc of plant material                                                    Methanol extract 
                                                                                                   (27.87 g) 
           Extracted with water by maceration (3 x 1.5 L) 
              
   
Marc of plant material                                                        Water extract 
                                                                                                     (9.4 g) 
                                       
Figure 2.1.Schematic diagram of the extraction procedure of P. macrocarpa fruits 
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2.3.3. Antidiabetic evaluation of P. macrocarpa extracts  
2.3.3.1. Hypoglycaemic activity in normal rats 
     Glucose response to a single dose of the extracts (1 g/kg b.w.) compared to standard 
antidiabetic drugs was carried out in 30 overnight fasted normal rats (200-250 g). These 
rats were divided equally into five groups of six rats according to the following 
treatment:  
Group I served as a negative control and received normal saline, 10 mL/kg 
Group II served as a positive control and treated with glibenclamide, 10 mg/kg 
Group III received 1 g/kg b.w. of petroleum ether extract of P. macrocarpa  
Group IV received 1g/kg b.w. of methanol extract of P. macrocarpa 
Group V received 1 g/kg b.w. of water extract of P. macrocarpa 
      The extracts/drug/saline was administered orally via intra-gastric tube. Blood 
samples were collected from tail vein prior to dosing (0 hour) and then at 1, 2, 3, 5 and 7 
hours after dosing, for glucose level determination using a clinical glucose meter (Accu-
check Advantage II, Roche Diagnostics Co. USA). 
 
2.3.3.2. Intra-peritoneal glucose tolerance activity (IPGTT) in normal rats 
        Thirty Male Sprague Dawley rats (200–250 g) were equally divided into five 
groups (n=6) and fasted over night. The first group received normal saline 10 ml/kg as 
control. The second group was treated with metformin 500 mg/kg. The third, fourth and 
fifth groups received 1 g/kg petroleum ether extract, methanol extract and water extract 
of P. macrocarpa, respectively. After an hour, the rats were administrated glucose       
(1 g/kg b.w.) intra-peritoneally and blood samples withdrawn via tail nicking at times   
0 (before treatment), 15, 30, 45, 60, 90 and 120 minutes after the glucose loading for 
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determination of blood glucose level using Accu-check Advantage II (Roche 
Diagnostics Co. USA). 
 
 2.3.3.3. Anti-hyperglyceamic activity in streptozotocin - induced diabetic rats 
    Diabetes was induced in rats by intra-peritoneal injection of 65 mg/kg b.w. of 
streptozotocin (STZ) after an overnight fast folloing method described previously 
(Abdul-Razak et al., 2002). 72 hours after streptozotocin administration, blood glucose 
level was measured. Rats with fasting blood glucose ≥ 15 mmol/L were considered 
diabetic and used for the study.   
 Forty two (42) diabetic and 6 non diabetic rats were assigned into 8 groups of 6 rats 
each and treated as shown below.  
Group1:       6 normal rats treated with normal saline 10 mL/kg b.w.  
Group2:       6 Diabetic rats treated with normal saline 10 ml/kg b.w. 
Group3:      6 Diabetic rats treated with glibenclamide 10 mg/kg b.w. 
Group4:      6 Diabetic rats treated with metformin 250 mg/kg b.w. 
Group5:      6 Diabetic rats treated with insulin 5 I.U./kg b.w. 
Group6:      6 Diabetic rats treated with petroleum ether extract of P.macrocarpa 1 
g/kg.  
Group7:      6 Diabetic rats treated with methanol extract P.macrocarpa 1 g/kg b.w.  
Group8:      6 Diabetic rats treated with water extract P.macrocarpa 1 g/kg b.w. 
       Treatment was once a day, and lasted for 12 days. While the drug/extracts were 
administered via intra-gastric oral tube, insulin was given subcutaneous. Blood glucose 
during treatment period (3rd, 6th, 9th
 
days) and at end of study 12th
 
day was monitored 
using Accu-check Advantage II with tail vein blood. 
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2.3.3.4. Dose response relationship of most active extract (methanol extract of 
               P. macrocarpa) 
 
    Rats were divided into five groups and treated as follows: 
Group1: Rats received normal saline 10 mL/kg as a negative control. 
Group2: Rats were treated with metformin 500 mg/kg as a positive control. 
Group3: Rats were treated with 250 mg/kg methanol extract of P. macrocarpa. 
Group4: Rats were treated with 500 mg/kg methanol extract of P. macrocarpa. 
Group5: Rats were treated with 1000 mg/kg methanol extract of P .macrocarpa. 
     After an hour, the rats were loaded with 1 g/kg glucose and blood glucose level was 
measured before treatment and after 15, 30, 45, 60, 90 and 120 minutes been loaded 
with glucose. 
 
2.3.4. Fractionation of methanol extract by using solvent-solvent extraction                 
           method 
 
 
       The methanol extract of P. macrocarpa was further fractionated as following: the 
methanol extract (110 gm) was first suspended 500 mL of water. Then the suspension 
obtained was poured into a 1L separatory funnel. The solution was extracted with 
chloroform (3×250 mL). The combined chloroform fraction was dried by using 
anhydrous sodium sulphate, followed by solvent evaporation in a rotary evaporator. 
      The aqueous layer was then extracted with ethyl acetate (3×250 mL). The 
combined ethyl acetate fraction was washed with water, dried over anhydrous sodium 
sulphate and concentrated further with rotary evaporator. 
        Finally, the aqueous layer was extracted with n-butanol (5×250 mL). Then, the 
combined n-butanol fraction was concentrated using the rotary evaporator. The 
remainder aqueous was also concentrated in rotary evaporator. Concentrated fractions 
